SREBF2 Antibody

What is the difference between antibodies targeting N-terminal versus C-terminal regions of SREBF2?

N-terminal and C-terminal SREBF2 antibodies serve distinct research purposes based on SREBF2's biological processing:

• N-terminal antibodies: Detect both full-length (precursor) SREBF2 (~124 kDa) and the mature/cleaved form (mSREBP-2) (~60-70 kDa). These antibodies are essential for studying SREBF2 activation and nuclear translocation.

• C-terminal antibodies: Primarily recognize the full-length precursor form and the C-terminal fragment that remains after cleavage. These antibodies are valuable for examining SREBF2 processing and membrane association.

Research has shown that using both antibody types provides complementary data. For example, a study on Alzheimer's disease found "significant decrease in the nuclear translocation of N-terminal SREBP-2 accompanied by a significant accumulation of C-terminal SREBP-2 in NFT-containing pyramidal neurons" . This dual antibody approach revealed disrupted SREBF2 processing in neurodegenerative disease.

How do I validate the specificity of my SREBF2 antibody?

Rigorous validation ensures experimental reliability through multiple complementary approaches:

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before immunostaining, as described in research where "an adsorption experiment was performed by incubating diluted SREBP-2 antibody with 5 micrograms of peptide for 16 h before immunostaining" .

• Multiple antibody verification: Compare results from antibodies targeting different epitopes of SREBF2.

• Western blot profile analysis: Verify detection of expected molecular weight bands (precursor form at ~124 kDa and mature form at ~60-70 kDa) .

• Genetic manipulation controls: Use SREBF2 knockdown/knockout samples or overexpression systems as positive and negative controls.

• Cross-reactivity assessment: Confirm the antibody doesn't cross-react with the related protein SREBF1 .

What are the optimal applications for different forms of SREBF2 antibodies?

The experimental application should determine antibody selection based on validated performance:

For the most reliable results, researchers should use antibodies specifically validated for their application of interest, as demonstrated in studies using "SREBP2 antibody that was validated by peptide competition" .

How should I design experiments to detect SREBF2 activation in response to cholesterol perturbations?

SREBF2 activation experiments require careful methodological planning:

• Experimental timeline: Allow sufficient time for SREBF2 processing after treatment (typically 6-24 hours).

• Nuclear fractionation protocol: "Western blot analysis of the human cortical homogenates with the N-terminal SREBP-2 antibody revealed several bands between 55 and 68 kDa and one weak band around 125 kDa. The bands between 55 and 68 kDa were also found in the nuclear fraction which likely represent the mSREBP-2" .

• Complementary readouts:

  • Immunofluorescence showing nuclear translocation

  • Western blot of nuclear and cytoplasmic fractions

  • qPCR of SREBF2 target genes (e.g., HMGCR, LDLR)

• Pharmacological tools: Include positive controls using statins or cholesterol depletion treatments that activate SREBF2.

• Inhibitor controls: Use specific inhibitors of SREBF2 processing (e.g., fatostatin) as negative controls.

Why do I detect multiple bands on Western blots with my SREBF2 antibody?

Multiple bands are expected due to SREBF2's complex processing and require careful interpretation:

• Expected bands:

  • Full-length precursor: ~124 kDa

  • Mature/processed N-terminal form: ~60-70 kDa

  • Additional bands representing post-translational modifications or proteolytic fragments

• Validation approach: "Western blot analysis of SREBP2/SREBF2 using anti-SREBP2/SREBF2 antibody (A01678-2) showed distinct bands at approximately 68 kDa across multiple human cell lines and rodent tissue lysates" .

• Common issues and solutions:

  • Degradation products: Use fresh samples and protease inhibitors

  • Non-specific binding: Optimize blocking conditions and antibody concentration

  • Isoform detection: "At least three isoforms of SREBF2 are known to exist" , which may produce distinct banding patterns

• Resolution methods:

  • Subcellular fractionation to confirm localization

  • Use both N- and C-terminal antibodies for confirmation

  • Include appropriate positive controls (e.g., SREBF2 overexpression lysates)

How can I improve nuclear localization detection of SREBF2 in immunofluorescence studies?

Nuclear localization is critical for studying SREBF2 activation and requires optimized protocols:

• Fixation optimization: "To facilitate intracellular staining, cells were fixed with 4% paraformaldehyde and permeabilized with permeabilization buffer" .

• Permeabilization protocol: Use 0.1-0.5% Triton X-100 for adequate nuclear penetration.

• Blocking conditions: "The cells were blocked with 10% normal goat serum. And then incubated with rabbit anti-SREBP2/SREBF2 Antibody" .

• Antibody selection: Use validated N-terminal antibodies known to detect nuclear SREBF2.

• Counterstaining strategy: "Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red) and counterstained with DAPI (blue). Specific staining was localized to cell surfaces and cytoplasm" .

• Control treatments: Include positive controls (statin treatment) and negative controls (SREBF2 inhibitors).

• Quantification approach: "Densitometric quantification was performed with the N-terminal antibody, comparing the staining intensity in neurons with or without tau-positive NFT" .

How can SREBF2 antibodies be used to investigate its role in neurodegenerative diseases?

SREBF2 has emerging roles in neurodegenerative pathologies that can be investigated using specific antibody-based approaches:

• Dual antibody strategy: "Two specific SREBP-2 antibodies, either recognizing the N-terminus or the C-terminus, were used. We found a significant decrease in the nuclear translocation of N-terminal SREBP-2 accompanied by a significant accumulation of C-terminal SREBP-2 in NFT-containing pyramidal neurons in AD" .

• Co-localization studies: "Comparison of the N-terminal SREBP-2 immunostaining with AT8, an antibody specific for phosphorylated tau, on adjacent serial sections in AD cases, revealed that AT8-positive NFTs had no or much reduced SREBP-2 immunoreactivity" .

• Animal model validation: "Reduced nuclear N-terminal SREBP-2 was also found in 3XTg AD mice and P301L Tau mice with tau pathology but not in CRND8 APP mice" .

• Mechanistic investigation: "We previously demonstrated that oligomeric amyloid β42 (oAβ42) inhibits the mevalonate pathway impairing cholesterol synthesis and protein prenylation... Overexpression of constitutively active Akt prevents the effect of oAβ42 on SREBP-2" .

• Quantitative analysis: "Densitometric analysis found that the NFT-containing neurons had significantly less SREBP-2 compared to AT8-free neurons" , providing quantitative evidence of SREBF2 dysregulation.

What are the methodological considerations for studying SREBF2 in cancer immunology research?

Recent research has revealed SREBF2's role in cancer immunology, requiring specialized experimental approaches:

• Cell type-specific analysis: "Utilizing CD63 as a unique surface marker, we demonstrate that mature regulatory DCs (mregDCs) suppress DC antigen cross-presentation while driving TH2 and regulatory T cell differentiation within tumor-draining lymph node tissues" .

• Metabolic pathway integration: "Transcriptional and metabolic studies show that mregDC functionality is dependent upon the mevalonate biosynthetic pathway and the master transcription factor, SREBP2" .

• Tumor microenvironment modeling: "Melanoma-derived lactate activates DC SREBP2 in the tumor microenvironment (TME) and drives mregDC development from conventional DCs" .

• Genetic silencing approach: "DC-specific genetic silencing and pharmacologic inhibition of SREBP2 promotes anti-tumor CD8+ T cell activation and suppresses melanoma progression" .

• Chromatin immunoprecipitation: "SREBP2/DNA complexes were immuno-precipitated using 5 µg Goat Anti-Human SREBP2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF7119) or control antibody (Catalog # AB-108-C) for 15 minutes in an ultrasonic bath" , which allows for direct analysis of SREBF2 transcriptional targets.

How can I design ChIP experiments to study SREBF2 transcriptional activity?

Chromatin immunoprecipitation (ChIP) experiments require careful consideration of SREBF2's unique properties:

• Antibody selection: Use ChIP-validated antibodies specifically designed for this application, such as "Mouse Anti-Human SREBP2 Monoclonal Antibody (Clone 1C6)" that has been validated for ChIP.

• Chromatin preparation: "HUVEC human umbilical vein endothelial cells were serum-starved for 5 hours, fixed using formaldehyde, resuspended in lysis buffer, and sonicated to shear chromatin" .

• Immunoprecipitation protocol: "SREBP2/DNA complexes were immuno-precipitated using 5 µg Goat Anti-Human SREBP2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF7119) or control antibody (Catalog # AB-108-C) for 15 minutes in an ultrasonic bath" .

• Controls and validation: "Immuno-complexes were captured using 50 µL of MagCellect Streptavidin Ferrofluid (Catalog # MAG999) and DNA was purified using chelating resin solution" .

• Target gene selection: Focus on known SREBF2-regulated genes involved in cholesterol biosynthesis or custom targets relevant to your research context.

• Data analysis approach: Quantitative PCR or next-generation sequencing can be used to analyze ChIP results, with appropriate normalization to input and control immunoprecipitations.

How can SREBF2 antibodies be incorporated into multi-omics research strategies?

Modern research requires integrating antibody-based techniques with other omics approaches:

• ChIP-Seq integration: "Detection of SREBP2-regulated Genes by Chromatin Immunoprecipitation. The ABCA1 promoter was detected by standard PCR" .

• Proteomics coupling: Combine immunoprecipitation with mass spectrometry to identify SREBF2 interacting partners.

• RNA-protein interaction studies: "RNA immunoprecipitation (RIP) analysis of RALY. The presence of lincNORS and 18s rRNA in the precipitated complex was detected by qPCR" , which can be adapted for SREBF2 studies.

• Metabolomics correlation: Link SREBF2 activation states with cholesterol and lipid metabolite profiles.

• Single-cell applications: Adapt SREBF2 antibody protocols for single-cell protein analysis, as demonstrated in flow cytometry applications using "rabbit anti-SREBP2/SREBF2 Antibody (A01678-2, 1 μg/1x106 cells) for 30 min at 20°C" .